{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:34Z","timestamp":1790931334591,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Sydney","id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of peptide receptor radionuclide therapy (PRRT) is well established in the treatment of advanced or unresectable neuroendocrine tumours (NETs) after progression on somatostatin analogues (SSA), with randomised clinical trials such as NETTER-1 and NETTER-2 showing improvement in progression free survival (PFS) as well as tumour response [12, 13]. Current landmark trials only considered patients suitable for PRRT if all known lesions displayed SSTR expression, via avidity on planar scintigraphy or Gallium-68 DOTATATE PET\/CT. However, there is a select group of patients with oligodiscordant disease (3 or less lesions which are FDG avid but not DOTATATE avid) on dual DOTATATE\/FDG PET imaging who may benefit from PRRT in combination with additional therapies such as liver directed therapy (LDT) or chemotherapy. There is currently no data regarding the efficacy and outcomes of PRRT in oligodiscordant disease. This study is the first to describe the treatment patterns and outcomes of patients with oligodiscordant disease receiving PRRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-centre retrospective review was performed in patients with advanced gastroenteropancreatic NETs with oligodiscordant disease who received at least one cycle of PRRT with [177Lu]Lu\u2013DOTA-TATE from 2020 to 2024. Safety was assessed by renal and haematological parameters (CTCAE v5.0) during PRRT, and at 3 months post completion of treatment. Response to treatment was evaluated on molecular imaging with Gallium-68 DOTATATE PET\/CT. Kaplan-Meier method was used to perform median progression free survival (PFS), overall survival (OS), and time to next treatment (TTNT) analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients met the inclusion criteria, the median age was 66 years, and 54% were male. Primary site: small bowel (7), pancreas (4), colorectal (2). WHO grade: none had grade 1 disease, ten grade 2 and three had grade 3 disease. Median OS was 27.3 months (95% CI 19.7 - not reached), median PFS 15.1 months (95% CI 7.1\u201320.1), and median TTNT 15.0 months (95% CI 6.7\u201339.6). One of 15 patients developed treatment related myeloid neoplasm on long term follow-up, confirmed by bone marrow biopsy. No patients developed significant renal toxicity on follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with advanced NETs with oligodiscordant disease identified on dual PET imaging, the combination of PRRT with systemic therapy or other therapies (surgery, liver directed therapy, radiotherapy) can be effective with acceptable toxicity and should be considered as a possible option for treatment in selected patients. The sequencing of treatment modalities and exact strategy employed is best decided at an experienced NET centre with multi-disciplinary input. Keywords: Neuroendocrine tumours, FDG PET, Dotatate PET, Peptide receptor radionuclide therapy, Discordant disease, Overall survival, Progression free survival, FDG avid disease<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08042-7","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:54:18Z","timestamp":1783302858000},"page":"6966-6976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1007","volume":"53","author":[{"given":"Claire","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sabahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie I.","family":"Diakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-3144","authenticated-orcid":false,"given":"David L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"8042_CR1","first-page":"16","volume-title":"Classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours: digestive system tumours","author":"DS Klimstra","year":"2019","unstructured":"Klimstra DS, Kloppell G, La Rosa S, WHO Classification of Tumours Editorial Board. Classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours: digestive system tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2019. p. 16.","edition":"5"},{"issue":"3","key":"8042_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.123.265706","volume":"65","author":"JR Strosberg","year":"2024","unstructured":"Strosberg JR, Al-Toubah T, El-Haddad G, Reidy Lagunes D, Bodei L. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine. 2024;65(3):340\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265706.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"key":"8042_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40336-019-00328-1","volume":"7","author":"F Muffatti","year":"2019","unstructured":"Muffatti F, Partelli S, Cirocchi R, et al. Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clin Transl Imaging. 2019;7:181\u20138. https:\/\/doi.org\/10.1007\/s40336-019-00328-1.","journal-title":"Clin Transl Imaging"},{"key":"8042_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.23469","volume":"112","author":"I Kayani","year":"2008","unstructured":"Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447\u201355. https:\/\/doi.org\/10.1002\/cncr.23469.","journal-title":"Cancer"},{"issue":"2","key":"8042_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrendo.2013.246","volume":"10","author":"M Van Essen","year":"2014","unstructured":"Van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nature reviews Endocrinology. 2014;10(2):102\u201314. https:\/\/doi.org\/10.1038\/nrendo.2013.246.","journal-title":"Nature reviews. Endocrinology"},{"key":"8042_CR6","first-page":"71","volume":"14","author":"MS Hofman","year":"2012","unstructured":"Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14:71\u201381.","journal-title":"Discov Med"},{"issue":"3","key":"8042_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1267\/ahc.12006","volume":"45","author":"G Mizutani","year":"2012","unstructured":"Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, et al. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. Acta histochemica et cytochemica. 2012;45(3):167\u201376. https:\/\/doi.org\/10.1267\/ahc.12006.","journal-title":"Acta histochemica et cytochemica"},{"issue":"7","key":"8042_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2967\/jnumed.124.269031","volume":"66","author":"DL Chan","year":"2025","unstructured":"Chan DL, Hayes A, Karfis I, Conner A, Mileva M, Bernard E, et al. [18F]FDG metabolic tumor volume as a prognostic marker in neuroendocrine neoplasm: a multicenter study. J Nucl Med. 2025;66(7):1012\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.269031.","journal-title":"J Nucl Med"},{"key":"8042_CR9","doi-asserted-by":"publisher","unstructured":"Alevroudis E, Spei ME, Chatziioannou SN, et al. Clinical Utility of 18\u2009F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers. 2021;13(8):1813. https:\/\/doi.org\/10.3390\/cancers13081813. PMID: 33920195; PMCID: PMC8069875.","DOI":"10.3390\/cancers13081813"},{"key":"8042_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2022","unstructured":"Chan DL, Hayes AR, Karfis I, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2022;128:549\u201355. https:\/\/doi.org\/10.1038\/s41416-022-02061-5.","journal-title":"Br J Cancer"},{"issue":"5","key":"8042_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149\u201358. https:\/\/doi.org\/10.7150\/thno.18068.","journal-title":"Theranostics"},{"issue":"12","key":"8042_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"issue":"10446","key":"8042_CR13","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"issue":"3","key":"8042_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309. https:\/\/doi.org\/10.1159\/000475526.","journal-title":"Neuroendocrinology"},{"issue":"7","key":"8042_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"key":"8042_CR16","doi-asserted-by":"publisher","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","DOI":"10.1200\/JCO.19.00201"},{"issue":"25","key":"8042_CR17","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8042_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","volume":"42","author":"R Kashyap","year":"2015","unstructured":"Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42(2):176\u201385. https:\/\/doi.org\/10.1007\/s00259-014-2906-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8042_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2967\/jnumed.123.266346","volume":"65","author":"DL Chan","year":"2024","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Mileva M, Bernard E, et al. [18F]FDG PET\/CT-avid discordant volume as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms: a multicenter study. J Nucl Med. 2024;65(2):185\u201391. https:\/\/doi.org\/10.2967\/jnumed.123.266346.","journal-title":"J Nucl Med"},{"issue":"11","key":"8042_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","volume":"55","author":"H Bahri","year":"2014","unstructured":"Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine. 2014;55(11):1786\u201390. https:\/\/doi.org\/10.2967\/jnumed.114.144386.","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"issue":"3","key":"8042_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","volume":"16","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1759.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8042_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392(7):653\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2403991.","journal-title":"N Engl J Med"},{"issue":"3","key":"8042_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MCG.0b013e3181a9f10a","volume":"44","author":"A Townsend","year":"2010","unstructured":"Townsend A, Price T, Yeend S, Pittman K, Patterson K, Luke C. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol. 2010;44(3):195\u20139. https:\/\/doi.org\/10.1097\/MCG.0b013e3181a9f10a.","journal-title":"J Clin Gastroenterol"},{"key":"8042_CR24","unstructured":"Everolimus. (2026) Pharmaceutical Benefits Scheme. Available at: https:\/\/www.pbs.gov.au\/medicine\/item\/10132G-10135K-11262R-11267B-11377T-2985D (Accessed: 08 December 2025)."},{"key":"8042_CR25","unstructured":"Cabozantinib. (2026) Medicine Status Website. Available at: https:\/\/www.pbs.gov.au\/medicinestatus\/document\/1387.html (Accessed: 01 January 2026)."},{"key":"8042_CR26","volume-title":"Quantification of volumetric phenotypes in dual PET for survival analysis of NENs","author":"J Chen","year":"2026","unstructured":"Chen J, Bernard E, Mokhtar S, Bailey D, Roach P, Chan J, Clifton-Bligh R, Diakos C, Gill A, Samra J, Pavlakis N, Chan D. Quantification of volumetric phenotypes in dual PET for survival analysis of NENs. Poland, Mar: Krakow; 2026. Poster D07."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08042-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:13Z","timestamp":1790929933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8042"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08042-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project was approved by the Northern Sydney Local Health District Human Research Ethics Committee (2024\/ETH01540).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was granted a waiver of informed consent by the Northern Sydney Local Health District Human Research Ethics Committee, in accordance with institutional and national ethical guidelines.","order":2,"name":"Ethics","label":"Consent to participate\/publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests or potential conflicts of interest to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}